See the latest news and media coverage for Can-Fite. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biopharmaceutical company developing oral drugs for oncology and inflammatory diseases
canfite.comLast updated
In short: Can-Fite advanced its clinical pipeline, reporting positive pancreatic cancer data and securing key patent allowances for its lead drug candidates.
The study will evaluate Namodenoson with immunotherapy in advanced pancreatic cancer, assessing progression-free survival, overall survival, and disease stabilization. Study design to be discussed at BIO convention.
Top-line results are expected in Q3 2026. The deal is worth up to $325M.
Highlights include positive Phase 2a pancreatic cancer data and a liver cancer patient with 9-year cancer-free survival.
Peer-reviewed study in International Journal of Obesity shows Namodenoson reduces weight gain in murine model.
Ramat Gan, Israel, April 30, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of...
Can-Fite stock jumps 20% after mid-stage data show namodenoson is well tolerated in advanced...
Can-Fite BioPharma's American depositary shares slid after its board of directors approved a 1-for-3,000 reverse share split. The ADSs were down 29% to 17 cents...
RAMAT GAN, Israel, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary...
Track Can-Fite and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.